Dyne Therapeutics (DYN) has received a new Buy rating, initiated by LifeSci Capital analyst, Francois Brisebois.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Francois Brisebois has given his Buy rating due to a combination of factors related to Dyne Therapeutics’ promising advancements in neuromuscular treatments. The company’s FORCE platform is pivotal in delivering therapies to muscle cells and the central nervous system, with Z-Basivarsen (DYNE-101) showing early signs of efficacy in treating myotonic dystrophy type 1 (DM1). This drug has demonstrated improvements in both functional and CNS benefits, which are crucial for its potential accelerated approval in the U.S. by mid-2026.
Additionally, Dyne Therapeutics is making strides in Duchenne Muscular Dystrophy (DMD) treatment with Z-Rostudirsen (DYNE-251), which has shown significant dystrophin expression and functional improvements. Despite only considering a portion of the DMD market in its valuation, the company is seen as undervalued. The recent FDA meeting has clarified the path for Z-Basivarsen’s approval, and the company’s focus on safety and tolerability, especially in comparison to competitors, further supports the Buy rating.
According to TipRanks, Brisebois is an analyst with an average return of -3.9% and a 37.07% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Avadel Pharmaceuticals, and Praxis Precision Medicines.
In another report released on October 6, Morgan Stanley also reiterated a Buy rating on the stock with a $48.00 price target.